Omega-3s and Omega-6s: It’s Not the Balance but the Levels That Matter

The omega battles never seem to end! Like a zombie that will not die, so is the idea that there is an ideal balance between the omega-6s and the omega-3s for which we should strive to achieve optimal health.

“The omega-3s wear white hats and the omega-6s black!” This idea was born in the 1960s when the enzymatic competition between the omega-3 alpha-linolenic acid (ALA) and the omega-6 linoleic acid (LA) was discovered, and it grew in the 1980s when a similar competition between arachidonic acid (AA, omega-6) and eicosapentaenoic acid (EPA, omega-3) for enzymes making prostaglandins and leukotrienes became clear. “LA could become AA, and it produced pro-inflammatory molecules, whereas ALA could become EPA, and it produced anti-inflammatory molecules”—what could be clearer?

Well, it turns out that research over the last 40 years has transformed this Dr. Seuss picture into the Mona Lisa… or maybe a Jackson Pollock splattergraph. This story is much more complicated and nuanced, and the old cops-and-robbers montage no longer applies.

Here are 4 reasons why the omega-6 to omega-3 ratio should be thrown into the garbage heap of scientific blunders.

1. LA is a heart- and brain-healthy fatty acid. This has been known for years¹ but ignored by self-styled nutrition experts who simply refuse to see it. What is the evidence for this? Much of it is contained in an AHA scientific statement on omega-6 fatty acids and heart health.¹ In addition, several recent studies looked at the association between blood levels of LA (a much better way to assess LA intake than asking folks what they ate last week) and a variety of health outcomes. They uniformly found that higher LA levels were significantly related to lower risk for cardiovascular disease,² type 2 diabetes,³ dementia,⁴ death from heart disease and cancer, and death from any cause for that matter.⁵ There is also an inverse—not direct—association between blood LA levels and multiple markers of inflammation⁶ that undermines the “LA is proinflammatory” hype. Since LA only gets into the blood by being eaten, these studies confirm that higher intakes of LA—which primarily come from seed oils like soybean, cottonseed, and corn oils—are associated with better health outcomes. So, the idea that LA—the primary omega-6 in the diet and the blood—is bad for you is the first shaky pillar of the omega-6:omega-3 ratio story. What’s the point of a ratio of good to good?
2. All omega-6s do the same thing (and ditto for omega-3s). This is patently untrue. It makes no sense to lump all 7 omega-6 fatty acids into one category (and all 5 omega-3s) and act as if they all have the same physiological effects. We know definitively that LA’s relationship to health is different from that of the other omega-6s.⁷
3. You can have the same ratio with an essentially infinite set of levels (blood or dietary) of omega-6 and omega-3 levels. Enough said.
4. Higher LA intakes will necessarily raise AA levels. And since AA is “pro-inflammatory”, more LA equals more inflammation. Neither of these assertions is true.^8,9

Rather than focusing on ratios, it is better to attend to EPA+DHA levels, whether in your food, your supplements, and especially in your blood. Where do these fatty acids come from? For omega-3s, it’s marine oils (whether from fatty fish, fish oils, krill oil, or algal oils). Plant sources of ALA include flax/chia, but these should never be viewed as substitutes for EPA and DHA.

How about the omega-6s? The vast majority of LA in our diet comes from seed oils—either directly (like in salad dressings) or indirectly (incorporated into hundreds of food products). Nuts and whole seeds are also good sources, but provide very little to the current diet. There is no strong evidence that the source of LA (or of EPA+DHA) is critically important: get these fatty acids from wherever you can.

The Bottom Line for Product Formulators

All of this discussion has very practical implications for formulators. Here’s how the “levels over ratios” perspective should influence fatty-acid product development:

1. Shift formulation goals from ratios to efficacy: Formulators no longer need to chase arbitrary omega-6:omega-3 ratios. The science supports delivering meaningful, clinically relevant amounts of EPA and DHA, since low omega-3 status—not excess omega-6—is usually the limiting factor. This simplifies formulations and allows clearer efficacy positioning.
2. Stronger justification for higher EPA+DHA dosages: Because outcomes track with absolute levels, products can be designed to help consumers reach evidence-based blood targets (e.g., Omega-3 Index ~8%), rather than token amounts that look good on a label but don’t move biomarkers.
3. Less pressure to eliminate omega-6s from blends: Omega-6s—especially LA—do not need to be excluded or minimized by default. This opens the door for balanced lipid systems (eg, functional oils, emulsions, chewables) without fear of being “pro-inflammatory,” as long as oxidation and quality are controlled.
4. Greater emphasis on stability, oxidation, and delivery: If levels matter, then bioavailability, protection from oxidation, and real-world absorption become central formulation priorities. Delivery technologies (emulsions, micelles, chewables, protected oils) that reliably raise blood EPA+DHA gain stronger scientific relevance.
5. Clearer, more defensible claims strategy: Messaging can move away from controversial “anti-seed oil” narratives and toward biomarker-driven outcomes, dose adequacy, and functional performance. This will resonate better with regulators, clinicians, sophisticated brands, and consumers.

Conclusion

The long-standing belief that health depends on achieving an ideal omega-6-to-omega-3 ratio needs to be challenged. The focus should instead be on absolute levels—especially of EPA and DHA. Decades of research show that LA (the primary dietary omega-6) is not inherently pro-inflammatory and is consistently associated with lower risk of cardiovascular disease, diabetes, dementia, and all-cause mortality.

Lumping fatty acids together into ratios oversimplifies complex biology and misrepresents how omega-3s and omega-6s actually function in the body. The practical takeaway: focus on increasing EPA and DHA intake while maintaining omega-6s from quality, minimally processed sources, rather than demonizing seed oils or chasing arbitrary ratios.

References

1. Harris WS, Mozaffarian D, Rimm EB, et al. Omega-6 fatty acids and risk for cardiovascular disease: a Science Advisory from the American Heart Association Nutrition Committee. Circulation. 2009;119(5):902-907. doi: 10.1161/CIRCULATIONAHA.108.191627
2. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality. Circulation. 2019;139(21):2422-2436. doi:10.1161/CIRCULATIONAHA.118.038908
3. Wu JHY, Marklund M, Imamura F, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017;5(12):965-974. doi:10.1016/S2213-8587(17)30307-8
4. Sala-Vila AT, NL, Westra J, et al. Plasma n6 polyunsaturated fatty acid levels and risk for dementia: a prospective observational study from the UK Biobank. Am J Clin Nutr. 2026;123(4):101220. doi:10.1016/j.ajcnut.2026.101220
5. Harris WS, Westra J, Tintle NL, et al. Plasma n6 polyunsaturated fatty acid levels and risk for total and cause-specific mortality: a prospective observational study from the UK Biobank. Am J Clin Nutr. 2024;120(4):936-942. doi:10.1016/j.ajcnut.2024.08.020
6. Lai HTM, Ryder NA, Tintle NL, et al. Red blood cell omega-6 fatty acids and biomarkers of inflammation in the Framingham Offspring Study. Nutrients. 2025;17(13):2076. doi:10.3390/nu17132076
7. Delgado GE, Marz W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids: opposing associations with risk-the Ludwigshafen Risk and Cardiovascular Health Study. J Clin Lipidol. 2017;11(4):1082-1090. doi:10.1016/j.jacl.2017.05.003
8. Rett BS, Whelan J. Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. Nutr Metab (Lond). 2011;8:36. doi:10.1186/1743-7075-8-36
9. Johnson GH, Fritsche K. Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet. 2012;112(7):1029-1041. doi:10.1016/j.jand.2012.03.029